

eTable 1

ICD-10 codes

Condition/Event	ICD-10 Code
Ischemic stroke	I63, I64
Hemorrhagic stroke	I60, I61, I62
Diabetes	E10, E11, E12, E13, E14
Hypertension	I10, I11, I12, I13, I15
Peripheral artery disease	I70, I71, I72, I73
Congestive heart failure	I50
Atrial fibrillation	I48
Myocardial infarction	I21, I22, U98
Thromboembolism	G45, H34, I65, I66, I74, N28.0, O88.2 I26, I80, I82, O22.3
Bleeding event	D62, H43.1, H45.0, I85.0, I98.3, K25.0, K25.2, K25.4, K25.6, K26.0, K26.2, K26.4, K26.6, K27.0, K27.2, K27.4, K27.6, K28.0, K28.2, K28.4, K28.6, K29.0, K62.5, K66.1, K92.0, K92.1, K92.2, M25.0, N02, N92, N93, N95.0, R04, R31, R58

eTable 2

Distribution of EuroSCORE in the different prosthesis types separated by sex. (The score was available in 23.2% of the mSAVR and bioSAVR patients, and 40.6% of the TAVR patients).

Prosthesis type	EuroSCORE	Women	Men
mSAVR (n=457)	0-4	68 (52.7%)	190 (57.9%)
	5-9	57 (44.2%)	128 (39.0%)
	10-14	4 (3.1%)	10 (3.0%)
	15-19	0	0
	>19	0	0
bioSAVR (n=2271)	0-4	94 (11.7%)	326 (22.3%)
	5-9	621 (77.0%)	1026 (70.0%)
	10-14	87 (10.8%)	102 (7.0%)
	15-19	4 (0.5%)	0
	>19	0	0
TAVR (n=956)	0-4	5 (1.1%)	8 (1.7%)
	5-9	219 (46.1%)	220 (45.7%)
	10-14	233 (49.1%)	226 (47.0%)
	15-19	17 (3.6%)	25 (5.2%)
	>19	1 (0.2%)	2 (0.4%)

eTable 3

Pharmaceutical exposure in mSAVR, bioSAVR and TAVR separated by sex, described as person time in years (percentage of total person-time)

Drug	mSAVR		bioSAVR		TAVR	
	Women	Men	Women	Men	Women	Men
Aspirin	128 (4.1%)	616 (8.2%)	9711 (53.2%)	15395 (55.3%)	1768 (53.3%)	1586 (50.4%)
ADP*-receptor blocking agent	23 (0.7%)	51 (0.7%)	635 (3.5%)	1139 (4.1%)	444 (13.4%)	574 (18.2%)
Warfarin	2657 (86.2%)	6659 (88.2%)	3763 (20.6%)	6423 (23.1%)	761 (22.9%)	823 (26.1%)
DOAC [§]	2 (0.1%)	11 (0.2%)	937 (5.1%)	1616 (5.8%)	306 (9.2%)	289 (9.2%)
Beta blocking agent	1304 (42.3%)	3643 (48.3%)	9235 (50.6%)	15504 (55.7%)	1841 (55.5%)	1880 (59.7%)
ACE/ARB [#]	1832 (59.4%)	4426 (58.6%)	13078 (71.6%)	18971 (68.2%)	2374 (71.5%)	2167 (68.8%)
Diuretics	858 (27.8%)	1261 (16.7%)	7233 (39.6%)	8581 (30.8%)	1912 (57.6%)	1657 (52.6%)

*ADP; adenosine diphosphate, §DOAC; direct oral anticoagulant treatment; #ACE/ARB; angiotensin converting enzyme inhibitor/angiotensin II receptor blocking agent